tqb3909
Small moleculeexperimental
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2021 (NCT04975204)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Apoptosis regulator Bcl-2INHIBITOR
BCL2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06245941 | Phase 1/Phase 2 (Phase 2) | May 13, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT07011186 | Phase 1/Phase 2 (Phase 2) | Apr 17, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06211751 | Phase 1 | Jan 31, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06165822 | Phase 1 | Dec 31, 2023 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT05959694 | Phase 1/Phase 2 (Phase 2) | Oct 11, 2023 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06106841 | Phase 1/Phase 2 (Phase 2) | Oct 5, 2023 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT05775575 | Phase 1/Phase 2 (Phase 2) | Mar 2, 2023 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT04975204 | Phase 1 | Nov 30, 2021 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 8 | 8 | 2 | 2021 |
1 organizations
Page 1 / 1